Pharmacoeconomics, 1170-7690

Journal

  1. 2018
  2. Makady, A., van Veelen, A., Jonsson, P., Moseley, O., D'Andon, A., de Boer, A., ... Goettsch, W. (2018). Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. Pharmacoeconomics, 36(3), 359-368. https://doi.org/10.1007/s40273-017-0596-z
  3. 2017
  4. 2016
  5. Dunlop, W. C. N., Mullins, C. D., Pirk, O., Goeree, R., Postma, M. J., Enstone, A., & Heron, L. (2016). BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles. Pharmacoeconomics, 34(10), 1051-1065. https://doi.org/10.1007/s40273-016-0427-7
  6. Bindels, J., Ramaekers, B., Ramos, I. C., Mohseninejad, L., Knies, S., Grutters, J., ... Joore, M. (2016). Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. Pharmacoeconomics, 34(3), 315-322. https://doi.org/10.1007/s40273-015-0346-z
  7. 2015
  8. Marshall, D. A., Burgos-Liz, L., Pasupathy, K. S., Padula, W. V., IJzerman, M. J., Wong, P. K., ... Osgood, N. D. (2015). Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. Pharmacoeconomics. https://doi.org/10.1007/s40273-015-0330-7
  9. 2014
  10. 2013
  11. 2012
  12. 2011
  13. van Baal, P. H. M., Wong, A., Slobbe, L. C. J., Polder, J. J., Brouwer, W. B. F., & de Wit, G. A. (2011). Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations. Pharmacoeconomics, 29(3), 175-187.
  14. 2009
  15. Van Asselt, A. D. I., Van Mastrigt, G. A. P. G., Dirksen, C. D., Arntz, A., Severens, J. L., & Kessels, A. G. H. (2009). How to deal with cost differences at baseline. Pharmacoeconomics, 27(6), 519-528. https://doi.org/10.2165/00019053-200927060-00007
  16. 2008
  17. de Vries, R., Daenen, S., Tolley, K., Glasmacher, A., Prentice, A., Howells, S., ... Postma, M. J. (2008). Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics, 26(1), 75-90.
  18. Heeg, B. M. S., Damen, J., Buskens, E., Caleo, S., de Charro, F., & van Hout, B. A. (2008). Modelling approaches - The case of schizophrenia: the case of schizophrenia. Pharmacoeconomics, 26(8), 633-648.
  19. 2007
  20. 2006
  21. Oude Voshaar, R. C., Krabbe, P. F. M., Gorgels, W. J. M. J., Adang, E. M. M., van Balkom, A. J. L. M., van de Lisdonk, E. H., & Zitman, F. G. (2006). Tapering off benzodiazepines in long-term users: an economic evaluation. Pharmacoeconomics, 24(7), 683-694.
  22. 2005
  23. 2004
  24. Tramarin, A., Campostrini, S., Postma, M., Calleri, G., Tolley, K., Parise, N., & de Lalla, F. (2004). A Multicentre Study of Patient Survival, Disability, Quality of life and Cost of Care. Pharmacoeconomics, 22(1), 43 - 53.
  25. Tramarin, A., Campostrini, S., Postma, MJ., Calleri, G., Tolley, K., Parise, N., ... Palladio Study Grp (2004). A multicentre study of patient survival, disability, quality of life and cost of care - Among patients with AIDS in northern Italy. Pharmacoeconomics, 22(1), 43-53.
  26. 2001
  27. van Enckevort, PJ., Zwaveling, JH., Bottema, JT., Maring, JK., Klompmaker, IJ., Slooff, MJH., & TenVergert, EM. (2001). Cost effectiveness of selective decontamination of the digestive tract in liver transplant patients. Pharmacoeconomics, 19(5), 523-530.
Previous 1 2 Next

ID: 729269